<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:xmi="http://www.omg.org/XMI" xmlns:pos="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmlns:cas="http:///uima/cas.ecore" xmlns:tweet="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos/tweet.ecore" xmlns:type8="http:///org/apache/uima/ruta/type.ecore" xmlns:morph="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/morph.ecore" xmlns:dependency="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/dependency.ecore" xmlns:type6="http:///de/tudarmstadt/ukp/dkpro/core/api/semantics/type.ecore" xmlns:type9="http:///org/apache/uima/trials/type.ecore" xmlns:noNamespace="http:///uima/noNamespace.ecore" xmlns:type="http:///de/tudarmstadt/ukp/dkpro/core/api/anomaly/type.ecore" xmlns:type7="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type.ecore" xmlns:type3="http:///de/tudarmstadt/ukp/dkpro/core/api/metadata/type.ecore" xmlns:type4="http:///de/tudarmstadt/ukp/dkpro/core/api/ner/type.ecore" xmlns:type5="http:///de/tudarmstadt/ukp/dkpro/core/api/segmentation/type.ecore" xmlns:type2="http:///de/tudarmstadt/ukp/dkpro/core/api/coref/type.ecore" xmlns:constituent="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/constituent.ecore" xmlns:chunk="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/chunk.ecore" xmi:version="2.0"><cas:NULL xmi:id="0"/><tcas:DocumentAnnotation xmi:id="2" sofa="1" begin="0" end="1556" language="x-unspecified"/><type9:ORR xmi:id="3" sofa="1" begin="752" end="757"/><type9:PFSMean xmi:id="4" sofa="1" begin="841" end="851"/><type9:PFSMean xmi:id="6" sofa="1" begin="1011" end="1021"/><type9:OSMean xmi:id="5" sofa="1" begin="891" end="902"/><type9:OSMean xmi:id="7" sofa="1" begin="1040" end="1051"/><cas:Sofa xmi:id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: Patients older than 75 years of age are usually excluded from&#13;&#10;metastatic colorectal cancer randomized studies. The OPTIMOX1 study evaluated&#13;&#10;FOLFOX7, a simplified (s) leucovorin (LV) and 5-fluorouracil (5FU) regimen&#13;&#10;(sLV5FU2) with high-dose oxaliplatin, in a new oxaliplatin stop-and-go strategy. &#13;&#10;An exploratory cohort of patients aged 76 to 80 years was included in the study.&#13;&#10;METHODS: In all, 620 previously untreated patients were randomized between&#13;&#10;FOLFOX4 until progression (arm A), or FOLFOX7 for 6 cycles, maintenance without&#13;&#10;oxaliplatin for 12 cycles, and reintroduction of FOLFOX7 (arm B).&#13;&#10;RESULTS: A total of 37 patients aged 76 to 80 years were included, 20 in arm A&#13;&#10;and 17 in arm B. The overall response rate (ORR) was 59.4%, comparable to younger&#13;&#10;patients (59%). Median progression-free survival (PFS) was 9.0 months and median &#13;&#10;overall survival (OS) was 20.7 months. These results did not differ from that in &#13;&#10;younger patients &lt; or =75 years in the OPTIMOX1 study with PFS 9.0 months (P =&#13;&#10;.63) and OS 20.2 months (P = .57). They experienced slightly more grade 3 of 4&#13;&#10;toxicity than younger patients: 65% versus 48% (P = .06), mainly with more&#13;&#10;neutropenia (41% vs 24%, P = .03) and neurotoxicity (22% vs 11%, P = .06).&#13;&#10;Tolerability, however, was manageable and no toxic death occurred in this elderly&#13;&#10;population.&#13;&#10;CONCLUSIONS: The efficacy of FOLFOX-based treatment was maintained in patients&#13;&#10;&gt;75 years with both FOLFOX regimens. The oxaliplatin stop-and-go management&#13;&#10;strategy performed well in this population."/><cas:View sofa="1" members="2 3 4 6 5 7"/></xmi:XMI>